Core Insights - The company expects to achieve its profitability target two years ahead of schedule, with a projected breakeven in 2025 [1][2] Financial Performance - In the first three quarters, the company's total revenue increased by 59.8% year-on-year, reaching 1.12 billion yuan, while the net loss narrowed by 74.78% to 72 million yuan [1] - Revenue from the core product, BTK inhibitor Oubatinib, reached 1.01 billion yuan in the first three quarters, surpassing the total revenue of the previous year [1] Strategic Partnerships - The company entered a licensing agreement with Prolium, which includes an upfront payment of 17.5 million USD and potential milestone payments totaling up to 503 million USD based on specific clinical and regulatory achievements [1] - A significant licensing agreement with Zenas regarding Oubatinib and other autoimmune pipeline products was established, with a total transaction value exceeding 2 billion USD, including an upfront payment of 100 million USD [2] Research and Development - Research and development expenses increased by 9.9% year-on-year, amounting to 680 million yuan for the first three quarters of 2025 [2] - The company aims to push five to six innovative drugs for approval and globalize three to four products, while developing five to ten differentiated clinical candidates [2] Cash Position - As of September 30, 2025, the company held approximately 7.76 billion yuan in cash and cash equivalents [2]

Core Insights - Nuo Cheng Jian Hua reported a significant revenue increase of 59.8% year-on-year for the first three quarters of 2025, reaching 1.12 billion yuan, primarily driven by the sales growth of its core product, the BTK inhibitor Aobutini (Yinokai®) [2][5] - The company expects to achieve breakeven for the entire year of 2025, two years ahead of its profitability target, supported by strong revenue growth and improved cost efficiency [2][5] Financial Performance - Aobutini's revenue for the first three quarters increased by 45.8% year-on-year, totaling 1.01 billion yuan, surpassing the total revenue for the previous year [2] - The company's loss narrowed significantly by 74.8%, down to 70 million yuan, due to rapid revenue growth and enhanced cost management [2] Globalization Strategy - Nuo Cheng Jian Hua is accelerating its globalization efforts, having completed two major licensing agreements this year, including a significant deal with Zenas for Aobutini and other autoimmune pipeline products [3][4] - The agreement with Zenas includes an upfront payment of 100 million USD and potential milestone payments, with the total deal value exceeding 2 billion USD [3] Product Pipeline and Market Position - The company is strengthening its leadership in the hematological oncology market with Aobutini, Tanshizhu Single Antibody (Mingnuokai®), and Mesutoclax, covering multiple indications [6] - Aobutini has been approved for first-line treatment of CLL/SLL, enhancing its market position [6][7] - Tanshizhu Single Antibody has been fully commercialized in China, providing a new treatment option for R/R DLBCL patients [8] Clinical Development - Mesutoclax is undergoing multiple clinical trials, showing significant potential in treating CLL/SLL and AML, with promising efficacy and safety data [9][10] - The company is advancing several Phase III clinical trials for autoimmune diseases, including Aobutini for primary progressive multiple sclerosis (PPMS) and immune thrombocytopenic purpura (ITP) [12][14] Innovation and R&D - Nuo Cheng Jian Hua is committed to innovation, with a 9.9% increase in R&D expenses, reaching 680 million yuan in the first three quarters of 2025 [19] - The company plans to submit 5 to 7 clinical trial applications for new drug candidates in 2026, focusing on oncology and autoimmune diseases [20]

InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 董事名單與其角色及職能 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）成員載列如下： 獨立非執行董事 胡蘭女士 董丹丹博士 管坤良教授 董事會設立三個董事委員會。下表載列各董事會成員在該等委員會中所擔任 的職位： 執行董事 崔霽松博士 （主席兼行政總裁） 趙仁濱博士 非執行董事 施一公博士 謝榕剛先生 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 崔霽松博士 | | M | C | | 趙仁濱博士 | | | | | 施一公博士 | | | | | 謝榕剛先生 | M | | | | 胡蘭女士 | C | C | | | 董丹丹博士 | M | M | M | | 管坤良教授 | | | M | 附註： C 相關董事會轄下委員會的主席 M 相關董事會轄下委員會的成員 香港，2025年11月13日（星期四） ...

公司核心产品奥布替尼(宜诺凯® )销售收入持续增长，2025 年 1-9 月共实现其销售收入 10.10 亿元，同 比增长 45.77%。 智通财经APP讯，诺诚健华(09969)公布2025年第三季度业绩，营业收入约3.84亿元，同比增长38.09%; 归属于上市公司股东的净亏损为3432.35万元，基本每股亏损0.02元。1-9月，营业收入为约11.15亿元， 同比增长59.85%;归属于上市公司股东的净亏损约6441.49万元，同比收窄76.61%。 ...

Core Insights - The company reported a 59.8% year-on-year increase in total revenue for the first three quarters of 2025, reaching 1.12 billion RMB, driven by the continued growth in sales of its core product, BTK inhibitor Oubatinib (Yinokai®), and an upfront payment from a licensing agreement with Prolium [1] Revenue Performance - Oubatinib's revenue for the first three quarters increased by 45.8% year-on-year, amounting to 1.01 billion RMB, surpassing the total revenue of the previous year, attributed to the expanding market for its exclusive indication of marginal zone lymphoma (MZL) and the approval of new indications for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [1] Loss Reduction - The company's losses significantly narrowed by 74.8%, reducing to 0.07 billion RMB, primarily due to rapid revenue growth and improved cost efficiency [1]

诺诚健华医药有限公司管理层评论说：公司是一家以卓越的自主研发能力为核心驱动力的高科技创新生 物医药企业，拥有全面的研发、生产和商业化能力，专注于肿瘤和自身免疫性疾病等存在巨大未满足临 床需求的领域，在全球市场内开发具有突破性潜力的同类首创或同类最佳药物。 格隆汇11月13日丨诺诚健华(09969.HK)公告，2025年1-9月公司总营业收入11.15亿元，比上年同期增长 59.85%，毛利率为88.8%，比上年同期的86.0%提高了2.8个百分点。营业收入与毛利率的高速增长主要 为核心产品奥布替尼(宜诺凯)销售收入持续增长以及公司与Prolium Bioscience Inc.(以下简称"Prolium") 达成授权许可的首付款所致。公司2025年1-9月的净亏损为0.72亿元，比上年同期亏损收窄74.78%。 ...

崔霽松博士 （主席兼行政總裁） 趙仁濱博士 非執行董事 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 董事名單與其角色及職能 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）成員載列如下： 執行董事 施一公博士 謝榕剛先生 獨立非執行董事 胡蘭女士 董丹丹博士 管坤良教授 董事會設立三個董事委員會。下表載列各董事會成員在該等委員會中所擔任 的職位： | | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 崔霽松博士 | | M | C | | 趙仁濱博士 | | | | | 施一公博士 | | | | | 謝榕剛先生 | M | | | | 胡蘭女士 | C | C | | | 董丹丹博士 | M | M | M | | 管坤良教授 | | | M | 附註： C 相關董事會轄下委員會的主席 M 相關董事會轄下委員會的成員 香港，2025年11月13日（星期四） ...

InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） (1)2025年第三季度季度報告 及 (2)提名委員會組成變動 本 公 告 乃 由 諾 誠 健 華 醫 藥 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.09(2)(a)條及第13.10B條及香港法例第571章證券及期貨條例第XIVA部的內幕 消息條文作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 2025年第三季度季度報告 茲載列本公司在上海證券交易所網站刊發的《諾誠健華醫藥有限公司2025年第 三季度報告》（「2025年第三季度報告」），僅供參閱。以下為本公司2025年第三 季度報告的原文，僅供參考。如有任何歧義，概以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒 ...

关于调整董事会提名委员会成员的公告 诺诚健华医药有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-038 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | | | 调整前 | Jisong | Cui（崔霁松）博士（主席）、胡兰女士、 | | --- | --- | --- | --- | | 董事会提名 | | 董丹丹博士 | | | 委员会 | 调整后 | Jisong | Cui（崔霁松）博士（主席）、董丹丹博士、 | | | | Kunliang | Guan（管坤良）教授 | 特此公告。 诺诚健华医药有限公司董事会 2025 年 11 月 14 日 1 诺诚健华医药有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开董事 会，审议通过《提名委员会成员变动》的议案，现将有关情况公告如下： 鉴于香港联交所上市规则附录 C1 所载企业管治守则的修 ...

Core Viewpoint - Nocera Biopharma (688428) reported significant revenue growth and reduced net loss in Q3 2025, indicating a positive trajectory towards profitability and sustainable growth [1] Financial Performance - The company achieved a revenue of 1.115 billion yuan in the first three quarters, representing a year-on-year increase of 59.85% [1] - The net loss for the same period was 72 million yuan, which is a 74.78% reduction compared to the previous year [1] Revenue Drivers - The revenue growth was primarily driven by the continued sales increase of the core product, BTK inhibitor Acalabrutinib (Yinokai), and an upfront payment from a licensing agreement with Prolium [1] - Acalabrutinib's revenue for the first three quarters rose by 45.8% year-on-year, reaching 1.01 billion yuan, surpassing the total revenue of the previous year [1] Future Outlook - The company anticipates achieving breakeven for the full year 2025, two years ahead of its profitability target, supported by strong revenue growth, strict cost management, and a significant licensing deal with Zenas in early October [1] - This positions the company well for sustainable profitability and accelerated globalization [1]